Where does Novmetapharma Co., Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novmetapharma Co., Ltd ranks #20,170 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novmetapharma Co., Ltd hold?

Novmetapharma Co., Ltd holds 14 US utility patents granted between 2018 and 2024, spanning 8 technology areas.

What is Novmetapharma Co., Ltd's Innovation Score?

Novmetapharma Co., Ltd has an Innovation Score of 46.8 out of 100 (top 20% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novmetapharma Co., Ltd focus on?

Novmetapharma Co., Ltd's top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 13 patents, ranking #1,747 of 7,163 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Novmetapharma Co., Ltd's patent grant rate increasing or decreasing?

Novmetapharma Co., Ltd's recent grant velocity is +1200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Novmetapharma Co., Ltd's patents?

Novmetapharma Co., Ltd's patents average 12.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novmetapharma Co., Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novmetapharma Co., Ltd

USPTO PatentsView assignee record - 14 granted patents across 8 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novmetapharma ranks #20,170 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 8 technology areas.

#20,170
of 49,997 US assignees by volume: Top 20%
by Innovation Score (46.8/100): 12.4
avg claims per patent: +1200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20170 · Foreign Corporation #20,170 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #20,170/49,997
PHOTO-FINISH North America I M L…
CPC-NARROW A61K · 8 areas
INNOV-PAR 46.8/100
CLAIMS-RICH 12.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +1200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: North America I.M.L. Containers Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novmetapharma’s 46.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (20%) Velocity 20.0 pts (43%) Breadth 10.0 pts (21%) Claim depth 7.5 pts (16%)

Qualcomm Incorporated · highest

85
Novmetapharma · this assignee

47
3D Lighting… · lowest

7

What this shows Novmetapharma's Innovation Score is 46.8/100 (top 20% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novmetapharma?

Each dot is one of Novmetapharma’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novmetapharma’s own 12.4 claims/patent is at or below the 14.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Novmetapharma vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novmetapharma's grants concentrate

Novmetapharma Co., Ltd is a focused PatentsView assignee: 8 CPC subclasses with 92.9% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2018. By volume, Novmetapharma sits between North America I.M.L. Containers Inc. and Nurix Therapeutics, Inc..

Novmetapharma's three-year grant acceleration

Novmetapharma Co., Ltd shows 10 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

North America I M…

14
Nota

14
Novasolix

14
Novatek IP

14
Novus Scientific…

14
NSI International

14
NTT Data Services

14
Nurix Therapeutics

14
Novmetapharma ◀

14

What this shows Novmetapharma holds 14 patents at rank #20,147, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novmetapharma

By rank, the assignees closest to #20,147 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Novmetapharma's primary technology class.

Novmetapharma's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 20% higher than 80% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Novmetapharma Co., Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	7.1%
2020	2	14.3%
2021	1	7.1%
2022	3	21.4%
2023	4	28.6%
2024	3	21.4%

Which technologies does Novmetapharma Co., Ltd patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07K - Peptides 4

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 4

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 3

C07D - Heterocyclic Compounds 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novmetapharma Co., Ltd's patent record in context - here's where to go next.

Novmetapharma Co., Ltd's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 92.9% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #20,170 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novmetapharma Co., Ltd against North America I.M.L. Containers Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.